ClinicalTrials.gg
CompletedNCT03604705Updated Sep 16, 2025Results posted

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

A Phase 2 interventional study of APX001 in Candidemia, sponsored by Basilea Pharmaceutica. Completed at 29 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Basilea Pharmaceutica · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Candidemia with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Candidemia · United States.

Enrollment
24th of 27
21 · median 70
Started
2018
with 1 other
Phase 2
6 of 33
none open now
Registered
26th of 33
by date
Lead sponsor
2 of 33
Basilea Pharmaceutica

Among the 33 studies in Candidemia with a site in United States, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 26th registered.

Candidemia

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

Browse Candidemia studies →

Open to participants now

2 of the 33 studies in Candidemia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Candidemia with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in non-neutropenic patients 18 yeas of age and older.

Suspicion of antifungal-resistant candidemia is sufficient (documented resistance is not required for enrollment). The Study Drug Treatment Period of APX001 will be a maximum of 14 days. After completion of 14 days study drug therapy, if further antifungal treatment is indicated to complete treatment of candidemia in accordance with standard practice guidelines, fluconazole (unless susceptibility results warrant alternative antifungal therapy) may commence for up to a further 7 days. There will be a Follow up Period of 4 weeks (+4 days) after EOT. The total duration of participation in the study is up to approximately 7.5 weeks.

This study will be conducted at approximately 20 sites in the United States and globally.

03

Conditions studied

  • Candidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Provision of written consent
  • Adults ages 18 and above male or female
  • New diagnosis of candidemia
  • Able to have pre-existing intravascular catheters removed and replaced (as necessary)

Key Exclusion Criteria:

  • neutropenia
  • deep-seated Candida-related infections
  • hepatosplenic candidiasis
  • received more than 2 days of prior systemic antifungal treatment for current candidemia episode
  • severe hepatic impairment
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    APX001 Treatment

    Drug: APX001

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC)

    Treatment Success is defined as meeting all of the following criteria: Two consecutive blood cultures negative for Candida spp. Alive at EOST No concomitant use of any other systemic antifungal therapies through end of study treatment

    Time frame: One to forty-two days

Secondary outcomes

  1. Time to First Negative Blood Culture

    Time to first negative blood culture was defined as the number of days from first dose date of study drug to the date of first post-Baseline negative blood culture + 1. Patients without a negative blood culture at post-Baseline visits were censored at the last assessment date.

    Time frame: One to forty-nine days

  2. Percentage of Patients With Mycological Outcomes at End of Study Treatment (EOST), End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)

    Time frame: End of study treatment (EOST), end of treatment (EOT), and 2 and 4 weeks after end of treatment (EOT)

  3. Percentage of Patients With Treatment Success at End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)

    Time frame: 2 and 4 weeks after end of treatment (EOT)

  4. Overall Survival at Study Day 30

    Time frame: Day 30

  5. Number of Patients With Treatment Emergent Adverse Events (TEAEs)

    Time frame: One to forty-nine days

07

Results

Posted Aug 5, 2021

Participant flow

Participant flow — Overall Study
MilestoneAPX001 Treatment
Started21
Completed20
Not completed1

Outcome measures

PrimaryTreatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC)

Treatment Success is defined as meeting all of the following criteria: Two consecutive blood cultures negative for Candida spp. Alive at EOST No concomitant use of any other systemic antifungal therapies through end of study treatment

Time frame:
One to forty-two days
Reported as:
Count of participants · Participants
Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC)
ParticipantsTreatment Period - MITT
Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC)16
SecondaryTime to First Negative Blood Culture

Time to first negative blood culture was defined as the number of days from first dose date of study drug to the date of first post-Baseline negative blood culture + 1. Patients without a negative blood culture at post-Baseline visits were censored at the last assessment date.

Time frame:
One to forty-nine days
Reported as:
Mean · Days
Time to First Negative Blood Culture
DaysMITT Population
Time to First Negative Blood Culture2.4 ± 1.13
SecondaryPercentage of Patients With Mycological Outcomes at End of Study Treatment (EOST), End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)
Time frame:
End of study treatment (EOST), end of treatment (EOT), and 2 and 4 weeks after end of treatment (EOT)
Reported as:
Count of participants · Participants
Percentage of Patients With Mycological Outcomes at End of Study Treatment (EOST), End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)
ParticipantsEOST (End of Study Drug Treatment)EOT (End of Antifungal Treatment)Follow-up 2 Weeks After EOTFollow-up 4 Weeks After EOT
Percentage of Patients With Mycological Outcomes at End of Study Treatment (EOST), End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)161510
SecondaryPercentage of Patients With Treatment Success at End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)
Time frame:
2 and 4 weeks after end of treatment (EOT)
Reported as:
Number · percentage of participants
Percentage of Patients With Treatment Success at End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)
percentage of participantsTreatment Success 2 Weeks After EOTTreatment Success 4 Weeks After EOT
Percentage of Patients With Treatment Success at End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)60.055.0
SecondaryOverall Survival at Study Day 30
Time frame:
Day 30
Reported as:
Count of participants · Participants
Overall Survival at Study Day 30
ParticipantsMITT Population
Overall Survival at Study Day 3017
SecondaryNumber of Patients With Treatment Emergent Adverse Events (TEAEs)
Time frame:
One to forty-nine days
Reported as:
Count of participants · Participants
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
ParticipantsSafety Population
Number of Patients With Treatment Emergent Adverse Events (TEAEs)20

Adverse events

Collected over One to forty-nine days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population5/21 (23.8%)9/21 (42.9%)20/21 (95.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSafety Population
Septic shockInfections and infestations2/21
BacteraemiaInfections and infestations1/21
Bacterial sepsisInfections and infestations1/21
Enterobacter sepsisInfections and infestations1/21
Necrotising fasciitisInfections and infestations1/21
SepsisInfections and infestations1/21
Stenotrophomonas sepsisInfections and infestations1/21
Systemic candidaInfections and infestations1/21
Urinary tract infection bacterialInfections and infestations1/21
Cardiac failure congestiveCardiac disorders1/21
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSafety Population
DiarrhoeaGastrointestinal disorders3/21
VomitingGastrointestinal disorders3/21
Oedema peripheralGeneral disorders3/21
Pleural effusionRespiratory, thoracic and mediastinal disorders3/21
BacteraemiaInfections and infestations2/21
Septic shockInfections and infestations2/21
NauseaGastrointestinal disorders2/21
PyrexiaGeneral disorders2/21
DyspnoeaRespiratory, thoracic and mediastinal disorders2/21
Acute kidney injuryRenal and urinary disorders2/21

Baseline characteristics

Treatment Period - MITT

Age, Categorical
Age, Categorical(Participants)Treatment Period - MITT
<=18 years0
Between 18 and 65 years10
>=65 years10
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Period - MITT
Female7
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Period - MITT
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Period - MITT
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment Period - MITT
Belgium7
United States3
Israel9
Spain1
08

Study locations

29 sites
  • University of Alabama at Birmingham School of Medicine
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35249, United States
  • University of California, Davis
    Davis, California 95616, United States
  • University of California-Davis Medical Center
    Sacramento, California 95817, United States
  • Augusta University (Georgia Regents University)
    Augusta, Georgia 30901, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Duke University Hospital Medical Center
    Durham, North Carolina 27710, United States
  • University of Texas- Health Science Center and Medical School at Houston
    Houston, Texas 77030, United States
  • Institut Jules Bordet,Service De Microbiologie
    Brussels, 1000, Belgium
  • Hopital Erasme
    Brussels, 1070, Belgium
  • Institut Jules Bordet
    Brussels, Belgium
  • Universite Libre de Bruxelles (ULB) - Hopital Erasme
    Brussels, Belgium
  • CHU de Charleroi - Hopital Civil Marie Curie
    Lodelinsart, Belgium
  • Mont-Godinne University Hospital
    Yvoir, 5530, Belgium
  • University Hospital Mont-Godinne
    Yvoir, Belgium
  • Klinik I fur Innere Medizin- Uniklinik Koln
    Cologne, Germany
  • University Hospital Heidelberg
    Heidelberg, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik Haematologie/Onkologie
    Mainz, Germany
  • Infectious Diseases Unit, Rambam Medical Center
    Haifa, 3109601, Israel
  • Rambam Medical Center
    Haifa, Israel
  • Infectious Diseases Unit
    Tel Aviv, 6423906, Israel
  • Sourasky Medical Center
    Tel Aviv, Israel
  • Infectious Diseases Unit,Sheba Medical Center
    Tel Litwinsky, 52621, Israel
  • Sheba Medical Center
    Tel Litwinsky, Israel
  • Hospital Universitario Mutua de Terrassa
    Terrassa, Barcelona, Spain
  • Hospital General Universitario de Alicante
    Alicante, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital VLL D Hebron
    Barcelona, Spain
09

References and documents

Publications

  • Pappas PG, Vazquez JA, Oren I, Rahav G, Aoun M, Bulpa P, Ben-Ami R, Ferrer R, Mccarty T, Thompson GR, Schlamm H, Bien PA, Barbat SH, Wedel P, Oborska I, Tawadrous M, Hodges MR. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. J Antimicrob Chemother. 2023 Oct 3;78(10):2471-2480. doi: 10.1093/jac/dkad256. PubMed 37596890 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Mar 2020, 17 months.

Results were first posted in Aug 2021, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2018
First posted
Jul 27, 2018
StartActual
Oct 3, 2018
Primary completionActual
Mar 31, 2020
CompletionActual
Jul 2, 2020
Results first posted
Aug 5, 2021
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03604705
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Oct 3, 2018
Primary completion
Mar 31, 2020
Completion
Jul 2, 2020
Results posted
Aug 5, 2021
Last update
Sep 16, 2025

Study contacts

Marc Engelhardt
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosmanogepix

Start the discussion